Stromal Gene Signatures in Large-B-Cell Lymphomas
National Cancer Institute · National Institutes of Health · +12 more institutions
Indexed incrossrefpubmed
Abstract
Background
The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patients with diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear.
Methods
We profiled gene expression in pretreatment biopsy specimens from 181 patients with diffuse large-B-cell lymphoma who received CHOP and 233 patients with this disease who received R-CHOP. A multivariate gene-expression-based survival-predictor model derived from a training group was tested in a validation group.
Citation impact
1,810
total citations
- FWCI
- 51.73
- Percentile
- 100%
- References
- 34
Citations per year
Authors
50Topics & keywords
Topics
Keywords
- Vincristine
- Medicine
- Rituximab
- CHOP
- Prednisone
- Lymphoma
- Cyclophosphamide
- Doxorubicin
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.